You do know that's based in USD and they are only 12 months ahead but their selection criteria for patients is very rigid. I think you mean MU's IP for solid cancer is years ahead of ALA, if you are just valuing Azer-Cel given the current development is very close to registrational clinical trial, $2-300M is fair value.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
-0.002(10.7%) |
Mkt cap ! $93.33M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.3¢ | 1.2¢ | $166.1K | 13.36M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 53 | 14813222 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 7289912 | 23 |
View Market Depth
| Last trade - 13.54pm 23/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |